Alcheimera slimeiba teik diagnosticāta, izmontojūt vairuokys metodis, tymā skaitā ryupeigu mediciniskū izpieti, kognitivūs i neiropsihologiskūs testus, smedziņu attāluošonu i cytu īspiejamūs cālūņu nūvieršonu.
1. Medicinisks puorbaudejums: uorsts veiks fizisku puorbaudi i ryupeigi izzynuos veseleibys stuovūkli, kab nūsaceitu cytys īspiejamys atmiņu zuduma voi kognitivūs funkceju sasamazynuošonys īmeslis, par pīmāru, vairūgdzīdzieja problemys, vitaminu tryukums voi smedziņu audzieji.
2. kognitivī i neiropsihologiskī testi: itī testi nūviertej atmiņu, volūdu, problemu rysynuošonu i cytys kognitivys funkcejis, kab nūsaceitu kognitivūs trauciejumu apjūmu i atškiertu vacuma īmesļa atmiņu zaudiešonu nu demencejis.
Smedziņu attāluošona: magnetiskuo rezonanse (MRI) voi datorizātuo tomografeja (CT) var paleidzēt nūsaceit strukturaluos izmainis smedzīnī, kas var līkuotīs par Alcheimera slimeibu.
Liu SS, Zhu SQ: [Correlation between Alzheimer disease and cataract]. Zhonghua Yan Ke Za Zhi. 2017, 53 (4): 314-316.
Gauthier S: Practical guidelines for the antemortem diagnosis of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry. 1985, 9 (5-6): 491-5.
Rubin R: New Test to Help Diagnose Alzheimer Disease. JAMA. 2022, 327 (23): 2281.
[Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia]. Fortschr Neurol Psychiatr. 2022, 90 (7-08): 326-335.
Kapp MB: Physicians' legal duties regarding the use of genetic tests to predict and diagnose Alzheimer disease. J Leg Med. 2000, 21 (4): 445-75.
Britschgi M, Wyss-Coray T: Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol. 2009, 66 (2): 161-5.
Volicer L, Berman SA, Cipolloni PB, Mandell A: Persistent vegetative state in Alzheimer disease. Does it exist? Arch Neurol. 1997, 54 (11): 1382-4.
Imabayashi E, Saitoh Y, Tsukamoto T, Sakata M, Takano H: Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18 F-THK5351. Clin Nucl Med. 2022, 47 (12): 1066-1068.
Martínez A, Lahiri DK, Giacobini E, Greig NH: Advances in Alzheimer therapy: understanding pharmacological approaches to the disease. Curr Alzheimer Res. 2009, 6 (2): 83-5.
['Atsaceišona nu: medicinys']
['Itei interneta vītne ir dūmuota tikai izgleiteibys i informacejis īmeslim, i tei nateik skaiteita par medicinys pīduovuojumu voi profesionalu pakolpuojumu.']
['Pīduovuotū informaceju nadreikst lītuot, kab diagnosticātu voi izuorstātu kaidu slimeibu, i tim, kas meklej personeigu mediciniskū padūmu, juosazynoj ar licencātu uorstu.']
['Juopīzeist, ka neironu teikls, kas generej atbiļdis iz vaicuojumim, ir eipaši napareizs, kod runoj par skaitliskū saturu, par pīmāru, par konkretu slimeibu diagnozātūs cylvāku skaitu.']
['Vysod meklejit padumu nu sova uorsta voi cyta kvalificāta uorsta, kab saprostu jiusu slimeibu. Nikod naatsakuortojit profesionalū uorsta padumu voi aizkavejit tū mekliešonu deļtuo, ka esat koč kū izlasiejs itamā interneta vītnē. Ka jiusim ruodīs, ka jiusim var byut uorsteibys uorkuortys situaceja, zvaniet 911 voi īīt tyvuokajā uorstnīceibys centrā.']
['Atsaceišona: autortiesības']
['1998. goda Digitaluo tyukstūšgadis autoru tīseibu lykums, 17 U.S.C. § 512 (DMCA) nūdrūsynoj tīseibu aizstuoviešonu autoru tīseibu turātuojim, kuri skaita, ka materialā, kas pasaruoda iz škārsteikla, ir puorkuoptys jūs tīseibys saskaņā ar ASV autoru tīseibu lykumim. ']
['Ka jius iz lobu tycat, ka kaids saturs voi materials, kas ir pīejams saisteibā ar myusu sātom voi pakolpuojumim, puorkuop jiusu autortiesības, jius (voi jiusu aģents) jiusim var syuteit paziņuojumu, kurā lyugts svīgt itū saturu voi materialu voi bloķēt pīeju tam.']
['Paziņuojumi ir juonūsyuta e-postā (vērtīs sadaļu "Kontakti" e-posta adresei).']
['DMCA prasej, kab jiusu paziņuojumā par īspiejamu autortiesību puorkuopumu byutu īkļauta itei informaceja: (1) ar autortiesībām aizsorguotuo dorba aproksts, kas ir īspiejamuos puorkuopuma objekts; (2) īspiejamuos puorkuopuma satura aproksts i informaceja, kas ir pīteikama, kab ļautu mums atrast saturu; (3) jiusu kontaktinformaceja, tymā skaitā adrese, telefona numurs i e-posta adrese; (4) apstyprynuojums, ka jius asat puorlīcynuots, ka saturs tai, kai ir ībyldts, nav atļauts ar autortiesību eipašnīka voi juo aģenta voi kaida lykuma atbolstu; ']
['5. aplīcynuojumu, ka jiusu informaceja ir pareiza i ka jiusim ir tīseibys izmontuot autortīseibys, kuruos ir nūlīgts lītuot;']
['i 6) fizisks voi elektronisks autortīseibu turātuoja voi personas, kas ir pilnvarota dorbuotīs autortīseibu turātuoja vuordā, paraksts.']
['Lyudzu, syutiet mums e-postu ar sevkuru vaicuojumu/ieteikumu.']
How is alzheimer diagnosed?
Alzheimer's disease is diagnosed through a combination of methods, including a thorough medical evaluation, cognitive and neuropsychological tests, brain imaging, and the process of elimination of other possible causes.
1. Medical evaluation: A doctor will perform a physical examination and take a detailed medical history to rule out other possible causes of memory loss or cognitive decline, such as thyroid problems, vitamin deficiencies, or brain tumors.
2. Cognitive and neuropsychological tests: These tests assess memory, language, problem-solving, and other cognitive functions to determine the extent of cognitive impairment and to differentiate between normal age-related memory loss and dementia.
3. Brain imaging: Magnetic resonance imaging (MRI) or computed tomography (CT) scans can help identify structural changes in the brain that may indicate Alzheimer's disease.
Positron emission tomography (PET) scans can also be used to measure the levels of certain proteins associated with Alzheimer's disease.
4. Blood tests: Recent research has shown that certain blood tests can help diagnose Alzheimer's disease by measuring the levels of specific proteins or biomarkers associated with the disease.
5. Process of elimination: Since there is no single definitive test for Alzheimer's disease, diagnosis often involves ruling out other possible causes of dementia-like symptoms.
It is important to note that a definitive diagnosis of Alzheimer's disease can only be made after death through an examination of brain tissue.
However, current diagnostic methods can provide a high level of certainty for a clinical diagnosis while the person is still alive.
Early diagnosis is important for starting treatment and planning for the future.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
